China Central Lab Market Analysis by Clinical Trial Phase and Modality
According to Rohan Patil, who specializes in healthcare market research and clinical research services, with 5+ years of experience in market research and industry analysis. His research indicates that the China Central Lab Market is set to grow from USD 506.89 million in 2026 to USD 1,287.16 million by 2035, driven by increasing clinical trial activity, laboratory automation, AI integration, and demand for advanced biomarker and genomic testing. The analysis identifies safety testing, oncology studies, Phase III clinical trials, and biologics as the leading market segments, while advanced therapies and rare disease research present strong growth opportunities. China continues to strengthen its position as a global clinical research hub, with companies such as WuXi AppTec, KingMylab, Tigermed, Pharmaron, and Frontage Laboratories expanding capabilities and shaping the competitive landscape.
Last Updated : 19 June 2026
Category: Healthcare Services
Insight Code: 6922
Format: PDF / PPT / Excel